Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

GYN Oncology Research

Study Title:  A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma (Identifier: NCT01533207)

Study Purpose:  This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether combination therapy after surgery is an effective treatment for uterine leiomyosarcoma.

Principal Investigator: John P. Geisler, M.D. and Kelly Manahan, M.D.

Study Coordinator: Stephanie Smiddy, RN, CRC For more information, please contact 419.383.6794


 

Study Title:  A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial (Identifier: NCT01414608)

Study Purpose:  This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with locally advanced cervical cancer.

Principal Investigator: Kelly Manahan, M.D.

Study Coordinator: Stephanie Smiddy, RN, CRC For more information, please contact 419.383.6794


 

Study Title:  A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary. (Identifier: NCT00954174)

Study Purpose:  This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine or ovarian cancer.  

Principal Investigator: John P. Geisler, M.D. and Kelly Manahan, M.D.

Study Coordinator: Stephanie Smiddy, RN, CRC For more information, please contact 419.383.6794


 

Study Title:  A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer (Idnetifier: NCT01931670)

Study Purpose: The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).

Principal Investigator: Kelly Manahan, M.D.

Study Coordinator: Stephanie Smiddy, RN, CRC For more information, please contact 419.383.6794 

Last Updated: 6/17/14